PedAM
Pediatric Disease Annotations & Medicines
| Disease | lymphoma |
| Symptom | C0027947|neutropenia |
| Sentences | 10 |
| PubMedID- 23301757 | Randomized comparison of piperacillin-tazobactam plus amikacin versus cefoperazone-sulbactam plus amikacin for management of febrile neutropenia in children with lymphoma and solid tumors. |
| PubMedID- 25252614 | Background: the primary objective was to describe the total direct inpatient costs among solid tumor and lymphoma patients with chemotherapy-induced febrile neutropenia (fn) and the factors that were associated with higher direct cost. |
| PubMedID- 21472389 | Disseminated cryptococcosis in a non-hodgkin's lymphoma patient with late-onset neutropenia following rituximab-chop chemotherapy: a case report and literature review. |
| PubMedID- 26532567 | Cost-effectiveness analysis of granulocyte colony-stimulating factors for the prophylaxis of chemotherapy-induced febrile neutropenia in patients with non-hodgkin's lymphoma in greece. |
| PubMedID- 22972488 | Primary prophylaxis with granulocyte colony-stimulating factor (gcsf) reduces the incidence of febrile neutropenia in patients with non-hodgkin lymphoma (nhl) receiving chop chemotherapy treatment without adversely affecting their quality of life: cost-benefit and quality of life analysis. |
| PubMedID- 22563814 | Late-onset neutropenia following primary treatment of diffuse large b-cell lymphoma with rituximab-containing therapy. |
| PubMedID- 24684228 | History of chronic comorbidity and risk of chemotherapy-induced febrile neutropenia in patients with non-hodgkin lymphoma not receiving granulocyte colony-stimulating factor prophylaxis. |
| PubMedID- 22536253 | In a phase i/ii dose-finding study, activity was observed in heavily pretreated nhl and hodgkin lymphoma (hl) patients, with neutropenia (47%) reported as the most frequent grade 3 or 4 toxicity . |
| PubMedID- 22913768 | Economic costs of chemotherapy-induced febrile neutropenia among patients with non-hodgkin's lymphoma in european and australian clinical practice. |
| PubMedID- 21074471 | Recent data show that rituximab maintenance therapy significantly increases the risk of both infection and neutropenia in patients with lymphoma or other hematological malignancies. |
Page: 1